<DOC>
	<DOC>NCT00925015</DOC>
	<brief_summary>The purposes of this study are to assess the safety, tolerability, pharmacokinetic interactions and the Human Anti-Human Antibody of dalotuzumab in combination with cetuximab and irinotecan in patients with advanced or metastatic colorectal cancer in Japan.</brief_summary>
	<brief_title>Phase I Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Colorectal Cancer Patients (0646-016)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patient Is 20 Years Of Age Or Older Patient Has A Histologically Or Cytologically Confirmed Colorectal Cancer Patient Has Previously Failed Both Irinotecan And Oxaliplatin Containing Regimens And Should Have Progressed On Or Within 3 Months Of Completing Their Last Line Of Therapy With Objective Radiological Evidence Of Progression As Verified By Previous Radiologic Scans Patient Must Have Adequate Organ Function Patient Has Had Chemotherapy, Radiotherapy, Or Biological Therapy Within 4 Weeks Prior To Initial Dosing On This Study Or Whose Toxicities From Agents Administrated 4 Weeks Earlier Have Not Resolved To At Least Grade 1 Or Baseline Patient Has Experienced Intolerable Toxicity To Irinotecan Therapy Patient Has Prior Exposure To Igf1r Inhibitors Or Egfr Inhibitors (E.G. Cetuximab) Patient Is Concurrently Using Growth Hormone (Gh), Or Growth Hormone Inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>